PROCEPT BioRobotics (NASDAQ:PRCT) versus Stevanato Group (NYSE:STVN) Head to Head Comparison

PROCEPT BioRobotics (NASDAQ:PRCTGet Free Report) and Stevanato Group (NYSE:STVNGet Free Report) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.


This table compares PROCEPT BioRobotics and Stevanato Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
PROCEPT BioRobotics -66.12% -41.35% -27.92%
Stevanato Group 12.57% 12.61% 7.25%

Risk and Volatility

PROCEPT BioRobotics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.

Institutional and Insider Ownership

89.5% of PROCEPT BioRobotics shares are held by institutional investors. 17.4% of PROCEPT BioRobotics shares are held by insiders. Comparatively, 0.7% of Stevanato Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares PROCEPT BioRobotics and Stevanato Group’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PROCEPT BioRobotics $136.19 million 25.07 -$105.90 million ($2.12) -31.32
Stevanato Group $1.08 billion 5.54 $157.62 million €0.55 ($0.60) 36.95

Stevanato Group has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for PROCEPT BioRobotics and Stevanato Group, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PROCEPT BioRobotics 0 0 6 0 3.00
Stevanato Group 0 2 5 0 2.71

PROCEPT BioRobotics currently has a consensus target price of $61.20, suggesting a potential downside of 7.83%. Given PROCEPT BioRobotics’ stronger consensus rating and higher probable upside, equities analysts clearly believe PROCEPT BioRobotics is more favorable than Stevanato Group.

About PROCEPT BioRobotics

(Get Free Report)

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

About Stevanato Group

(Get Free Report)

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with's FREE daily email newsletter.